NEVVI Medicare utilization intelligence
or

← back

Provider profile

PARRA, ALBERTO MD

Hematology-Oncology · NPI 1376836718 · ARLINGTON, TX

1
Groups
35
Codes · 2024
54,579
Disclosed services

PARRA, ALBERTO is a Hematology-Oncology in ARLINGTON, TX, a member of 1 medical group, who billed 35 distinct codes to Medicare Part B in 2024.

Groups: ONCOLOGY HEMATOLOGY CONSULTANTS, PA (FORT WORTH, TX)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

54,579
disclosed services
35
codes billed to Medicare Part B
Prior year · CY2023 59,444 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
J1439 Injection, ferric carboxymaltose, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
96375 Injection of additional new drug or substance into vein
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J3315 Injection, triptorelin pamoate, 3.75 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
99426 Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96417 Administration of additional new drug or substance into vein, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
71260 Ct scan of chest with contrast
74177 Ct scan of abdomen and pelvis with contrast
J1200 Injection, diphenhydramine hcl, up to 50 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
71250 Ct scan of chest without contrast
74176 Ct scan of abdomen and pelvis without contrast
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
78306 Nuclear medicine study of bone and/or joint whole body
A9503 Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
99497 Advance care planning, first 30 minutes
G0136 Administration of a standardized, evidence-based social determinants of health risk assessment tool, 5-15 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.